Good morning and welcome to the Ironwood Pharmaceuticals Incorporated virtual stockholder meeting. I would like now to present our first speaker, Julie McHugh, Chair of the Board of Directors. Please go ahead. Good morning, ladies and gentlemen. I am Julie McHugh, Chair of the Board of Directors of Ironwood Pharmaceuticals Incorporated. Our annual meeting, as in prior years, is conducted in a virtual-only format, solely by means of a live audio webcast. I would like to welcome you and call to order the 2024 Annual Meeting of Stockholders of Ironwood Pharmaceuticals. I will act as Chair of this meeting, and John Minardo, SVP, Chief Legal Officer and Secretary of Ironwood, will act as Secretary and Inspector of Elections of the meeting. Before we get started, I will introduce the participants in today's meeting and then report on the call of the meeting. It is my pleasure to introduce the other members of the Board of Directors, certain officers, and invited guests who are participating in person or via teleconference for this annual meeting. Directors present, in addition to me, are Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Jay Shepard, and Ironwood CEO Thomas McCourt. Officers present, other than Mr. McCourt, are Sravan Emany, SVP, Chief Financial Officer. Andrew Davis, SVP, Chief Business Officer. John Minardo, SVP, Chief Legal Officer. Michael Shetzline, SVP, Chief Medical Officer and Head of Research and Drug Development. Also present from Ironwood Pharmaceuticals is Greg Martini, Vice President, Strategic Finance and Investor Relations, who will facilitate any discussion. Victoria Ford, partner of Ernst & Young LLP, is also present. This meeting was called by the Board of Directors of Ironwood. Notice of this meeting was furnished on or about April 25th, 2024, to every holder of record of the company's Class A Common Stock as of April 19th, 2024, the record date for this annual meeting. As previously mentioned, the Board of Directors has appointed Mr. Minardo as the Inspector of Elections for this meeting, and he has executed an appropriate oath of office. For the purposes of conducting this meeting today, it will be presumed that a quorum is present, subject to the final certification by the Inspector of Elections. Each share of Class A Common Stock is entitled to one vote on each of the proposals presented at this meeting. An alphabetical list of the registered shareholders as of April 19th, 2024, certified by the company's transfer agent, is available by clicking on the Registered Shareholder List link that is located in the center of the blue banner at the bottom of the Web portal for inspection by stockholders. At this time, I would like to turn the meeting over to Mr. Minardo, who will conduct the formal business of the meeting. Thank you, Ms. McHugh. We will first run through the specific proposals on the agenda for the meeting, during which time stockholders will have an opportunity to ask questions or comment on the proposals in the designated field on the web portal. Following the presentation and discussion of the proposals and voting, and the conclusion of the formal portion of the meeting, there will be an opportunity for stockholders to ask general questions. Please note we are recording this meeting. No other participant attending via webcast or telephone are permitted to use any audio recording device. Stockholders may vote online at this meeting by clicking on the voting button on the web portal and following the instructions there. Polls for voting on all matters are open at this time. Stockholders who executed written proxies or voted online or by telephone prior to this meeting do not need to vote again at the meeting unless they wish to change their vote. After all proposals have been considered at this meeting, the polls will close and no more votes will be accepted. We are now ready to proceed with the business of the meeting and consider the specific proposals for Ironwood, which were described in the company's 2024 proxy statement for the annual meeting of stockholders previously made available to you. No additional nominations or proposals were received in advance of this meeting in accordance with the company's bylaws and the Securities and Exchange Commission's proxy rules, so no other nominations or proposals will be considered today. I will now present the items on the agenda for this meeting and call for discussion and a vote with respect to each proposal. After all proposals have been presented, we will close the polls. The first proposal we will consider today is the election of nine directors to the Board of Directors of the company, as described in the company's 2024 proxy statement for the annual meeting of stockholders. The board has nominated Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, and Jay Shepard as directors, each to serve a one-year term ending at the 2025 Annual Meeting of Stockholders, and their successors are duly elected and qualified. The qualifications of the nominees are described in the proxy statement. The proposed resolution is as follows: that the nine nominees for director with the greatest number of votes cast for election are elected to the office of director of the company, each to serve for one year and until his or her successor is duly elected and qualified, or until their death, resignation, or removal. The names for election: Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, and Jay Shepard. The second proposal we will consider today is the approval by non-binding advisory vote of the compensation paid to the company's named executive officers, as disclosed in the company's 2024 proxy statement for the annual meeting of stockholders. The proposed resolution is as follows: that the company resolves that the compensation paid to the company's named executive officers, as disclosed in the company's 2024 proxy statement for the 2024 Annual Meeting of Stockholders, is approved on a non-binding advisory basis. The third proposal we will consider today is the ratification of our audit committee's selection of Ernst & Young LLP as the company's independent registered public accounting firm for 2024. The proposed resolution is as follows: resolves that the selection of Ernst & Young LLP as the company's independent registered public accounting firm for 2024 is ratified. That concludes the presentation of all the items on our agenda today. If any stockholder wishes to comment on or ask questions regarding the proposals being voted on today, please submit them in the designated field in the web portal. We will pause for a moment for questions. There are no questions or comments on the proposals. Thank you, Greg. There being no discussion on these proposals, we will now pause to allow for completion of voting. Again, we will pause for a moment for voting. Thank you. The polls for voting on all matters before this meeting are hereby closed as of 9:08 A.M. June 18th, 2024. As Inspector of Elections, I will now report on the preliminary voting results. Ladies and gentlemen, I have prepared the preliminary report of the Inspector of Elections. Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, and Jay Shepard have been duly elected as directors of the company, each by a plurality of the votes cast. Proposal number two was approved by a majority of the votes cast for and against said proposal. Accordingly, the stockholders have approved a non-binding advisory vote of the compensation paid to the company's named executive officers, as disclosed in the company's 2024 proxy statement for the annual meeting. Finally, proposal number 3 was approved by a majority of the votes cast for and against said proposal. Accordingly, the stockholders have ratified the selection of Ernst & Young LLP as the company's independent registered public accounting firm for 2024. After I prepare my final report as Inspector of Elections, the final voting results will be made available to the public through a Form 8-K filed with the SEC. Thank you, Mr. Minardo. There being no further business to come before the meeting, the 2024 Annual Meeting of Stockholders of Ironwood Pharmaceuticals Incorporated is now adjourned. Thank you, Ms. McHugh. With the meeting now adjourned, we will open the floor to stockholders who would like to ask questions on the web portal, and Mr. Martini will act as moderator. If you wish to address the meeting, please do so now in the designated field on the web portal. Are there any questions that anyone would like to ask of management? Please note that the question-and-answer period will last a maximum of 20 minutes total or such a period as Ms. McHugh deems appropriate. We will now pause for questions. There are no questions. With no questions from stockholders, we will now conclude this question-and-answer session. I want to thank all of you for attending today's annual meeting and for your continued support of Ironwood.